Lucideon Supports Wockhardt to Get the COVID-19 Vaccine to Market
Testing carried out at Lucideon's GMP testing laboratories and analytical chemistry facilities.
Lucideon was chosen by Wockhardt, the global pharmaceutical and biotechnology organisation, to support with testing of the COVID-19 vaccine.
What we delivered
Lucideon tested part of the Wockhardt-manufactured fill finished vaccines, to verify that they were in specification and therefore fit for use.
Testing was carried out at Lucideon's global headquarters in Stoke-on-Trent, home to its Good Manufacturing Practice (GMP) testing laboratories and UK analytical chemistry facilities.
From there, Lucideon undertook extensive method development and validation for the chemical testing required for the vaccine to be released to the market.
Value to the client
This work was of national and international significance and was carried out quickly and accurately. Effective regulatory compliance was essential to enable Wockhardt to get the vaccine doses to the market.
We implemented new working patterns and made extra resource available at our pharmaceutical centre of excellence in Stoke-on-Trent to meet that need, and to produce results promptly and safely.
As a global organisation, we are committed to working with our partners to fight COVID-19.